Ginkgo Bioworks (NYSE:DNA) Insider Sells $84,135.00 in Stock

Key Points

• Insider Activity: Ginkgo Bioworks insider Steven Coen sold 5,609 shares at an average price of $15.00, totaling $84,135, resulting in a 50.48% decrease in his ownership of the stock.
• Quarterly Earnings: The company reported a revenue of $49.60 million and earnings per share of ($1.10), surpassing analyst expectations.
• Institutional Investment: A significant 78.63% of Ginkgo Bioworks' stock is owned by institutional investors, with Headlands Technologies increasing its stake by 30% in the second quarter.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) insider Steven Coen sold 5,609 shares of the firm's stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $15.00, for a total value of $84,135.00. Following the sale, the insider directly owned 5,503 shares in the company, valued at approximately $82,545. This represents a 50.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ginkgo Bioworks Price Performance

Shares of NYSE:DNA traded up $0.17 during trading on Friday, hitting $16.14. 2,564,691 shares of the company's stock were exchanged, compared to its average volume of 1,556,445. The business's 50-day simple moving average is $12.30 and its 200 day simple moving average is $9.70. The company has a market cap of $955.43 million, a price-to-earnings ratio of -2.75 and a beta of 1.54. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.00 and a 52-week high of $16.85.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.44) by $0.34. Ginkgo Bioworks had a negative return on equity of 43.25% and a negative net margin of 136.56%.The business had revenue of $49.60 million during the quarter, compared to the consensus estimate of $41.60 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

Institutional Trading of Ginkgo Bioworks

A number of large investors have recently made changes to their positions in DNA. Headlands Technologies LLC increased its stake in Ginkgo Bioworks by 30.0% in the 2nd quarter. Headlands Technologies LLC now owns 40,818 shares of the company's stock worth $459,000 after buying an additional 9,408 shares during the period. Sender Co & Partners Inc. purchased a new position in shares of Ginkgo Bioworks during the second quarter worth approximately $312,000. Shay Capital LLC grew its stake in Ginkgo Bioworks by 6.2% in the second quarter. Shay Capital LLC now owns 19,382 shares of the company's stock worth $218,000 after purchasing an additional 1,124 shares in the last quarter. Engineers Gate Manager LP increased its holdings in Ginkgo Bioworks by 44.0% during the 2nd quarter. Engineers Gate Manager LP now owns 39,263 shares of the company's stock worth $442,000 after purchasing an additional 11,995 shares during the period. Finally, California State Teachers Retirement System lifted its holdings in shares of Ginkgo Bioworks by 10.0% in the 2nd quarter. California State Teachers Retirement System now owns 26,674 shares of the company's stock worth $300,000 after buying an additional 2,426 shares during the period. 78.63% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have commented on DNA. Weiss Ratings reiterated a "sell (d-)" rating on shares of Ginkgo Bioworks in a research note on Saturday, September 27th. Cowen reiterated a "buy" rating on shares of Ginkgo Bioworks in a research report on Friday, August 8th. Wall Street Zen raised Ginkgo Bioworks from a "sell" rating to a "hold" rating in a research note on Saturday, August 30th. Finally, BTIG Research lifted their price objective on Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a "sell" rating in a research note on Monday, August 25th. One analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Ginkgo Bioworks presently has a consensus rating of "Reduce" and a consensus price target of $9.00.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.